COMPARISON OF THE EFFECT OF A BIOSIMILAR BEVACIZUMAB WITH THE INNOVATORS’ BEVACIZUMAB IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER
Journal Title: European Journal of Biomedical and Pharmaceutical Sciences - Year 2019, Vol 6, Issue 2
Abstract
Aim: The role of bevacizumab in combination with carboplatin/paclitaxel chemotherapy has been established in patients with non-small-cell lung cancer (NSCLC). This trial was designed to compare the effect of the Zydus biosimilar bevacizumab with the reference bevacizumab in patients with NSCLC. Methods: A multicentre, prospective, randomized, open-label, active controlled study was carried out on 248 subjects with advanced, unresectable, recurrent or metastatic NSCLC at 28 sites across India. Subjects were randomized in a 2:1 ratio to receive intravenous infusion of 15 mg/kg of test or reference bevacizumab, plus paclitaxel 175 mg/m2 and carboplatin (AUC 5 mg/mL×min) every 3 weeks for 6 cycles. Overall response rate (ORR) after 6 cycles was assessed by using Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Pharmacokinetics, safety and tolerability, and immunogenicity were also assessed. Results: The ORR was 60.82% responders in the Zydus bevacizumab and 58.82% responders in the reference bevacizumab and the 90% confidence interval (CI) for the difference of ORR fell within the ±20% equivalence margin (-11.96, 15.97). The pharmacokinetic assessment of the Ln-transformed bevacizumab after Cycle-1 data showed the 90% CI for the ratio of the test to reference geometric least square mean fell within the 80.00-125.00% limits for Cmax (87.99%; 120.41%) and AUC0-t (90.70%; 122.03%). The incidence of immunogenicity was marginally lower in the test group as compared to the reference group (72.16% vs. 76.47%). Conclusion: The results demonstrated biosimilarity between Zydus and reference bevacizumab with respect to efficacy, tolerability and safety in the patients with NSCLC.
Authors and Affiliations
Dr. Deven Parmar
Keywords
Related Articles
- EP ID EP670320
- DOI -
- Views 110
- Downloads 0
VALIDATION OF HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) METHOD FOR DETERMINATION OF TRIMETAZIDINE IN PHARMACEUTICAL DOSAGE FORMS
A stability-indicating HPLC method was validated for the determination trimetazidine in tablet dosage form. The chromatographic conditions comprised of a 250 X 4.6 mm column containing 5-μm; packing L1 (C18), with a mobi...
THE HISTOLOGICAL ASSESSMENT OF CLARIAS GARIEPINUS’ GILLS: AN ECOTOXICOLOGICAL EVALUATION OF MGBUOBA FISH POND
Background: Aquatic toxicology is the study of the effects of manufactured chemicals, other anthropogenic, natural materials and activities on aquatic organisms at various levels of organization from subcellular through...
THE ROLE OF REHABILITATION AS AN ADJUNCT TO MEDICATION IN ACUTE CORONARY SYNDROMES
Purpose: The aim of this paper is to assess the impact of cardiac rehabilitation through a systematic review comparing cardiac rehabilitation to pharmacological treatment assessing the benefits and risks associated with...
SYNTHESIS AND ANTIFUNGAL ACTIVITIES OF BENZIMIDAZOLYL-ARYLPROPENONE SCAFFOLDS AS PROMISING INHIBITORS OF AZOLE-RESISTANT CANDIDA STRAINS
In the general context of the emergence of strains resistant to currently available antifungal drugs, we herein report the synthesis and the antifungal activities of some benzimidazoles-arylpropenones against three Azole...
ASSESSMENT OF G6PD AND CBC PARAMETERS AMONG SUDANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS
Back ground: Diabetes mellitus (DM) is a common and complicated disease with increasing prevalence especially in developing countries. Complications of DM impose heavy health and financial burden on society. The definiti...